Following an abbreviated submission.
Vinorelbine capsule (Navelbine®) is accepted for restricted use within NHS Scotland for treatment of advanced breast cancer stage III and IV relapsing after, or refractory to, an anthracycline-containing regimen. It is restricted to use by specialist oncologists as an alternative to the intravenous formulation of vinorelbine where vinorelbine is considered to be appropriate. It is more expensive than the intravenous formulation of vinorelbine. However, its use may allow changes to service delivery that have individual patient or organisational benefits.
Download detailed advice24KB (PDF)
- Medicine name:
- vinorelbine soft capsules (Navelbine Oral)
- SMC ID:
- Advanced breast cancer stage III and IV
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 13 August 2007